share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外国发行人报告
美股SEC公告 ·  06/13 08:33
Moomoo AI 已提取核心信息
Alterity Therapeutics, a biotechnology company specializing in treatments for neurodegenerative diseases, announced that its CEO, David Stamler, M.D., will present at the MST Access 'Hidden Gems in Life Sciences' webinar. The presentation is scheduled for June 13, 2024, in Australia and June 12, 2024, in the United States. The company, which is in the clinical stage of developing its lead asset, ATH434, for treating Parkinsonian disorders, will offer an overview of its operations and developments. Investors will have the opportunity to ask questions during the webinar, and a recording will be available on Alterity's website post-event. The announcement was authorized by CEO David Stamler and is part of a Form 6-K report filed with the SEC, which is also incorporated by reference into the company's various registration statements.
Alterity Therapeutics, a biotechnology company specializing in treatments for neurodegenerative diseases, announced that its CEO, David Stamler, M.D., will present at the MST Access 'Hidden Gems in Life Sciences' webinar. The presentation is scheduled for June 13, 2024, in Australia and June 12, 2024, in the United States. The company, which is in the clinical stage of developing its lead asset, ATH434, for treating Parkinsonian disorders, will offer an overview of its operations and developments. Investors will have the opportunity to ask questions during the webinar, and a recording will be available on Alterity's website post-event. The announcement was authorized by CEO David Stamler and is part of a Form 6-K report filed with the SEC, which is also incorporated by reference into the company's various registration statements.
专注于神经退行性疾病治疗的生物技术公司Alterity Therapeutics宣布，其首席执行官David Stamler医学博士将在MST Access“生命科学中的隐藏宝石”网络研讨会上发表演讲。该演讲定于2024年6月13日在澳洲和2024年6月12日在美国举行。该公司正在临床阶段开发其主要资产ATH434，用于治疗帕金森氏综合征，将提供其运营和发展概述。投资者将有在网络研讨会期间问问题的机会，活动后Alterity的网站上还将提供录音。该公告获得首席执行官David Stamler的授权，并作为提交给美国证券交易委员会的6-K表格的一部分，该表格也被纳入公司各种登记声明之中。
专注于神经退行性疾病治疗的生物技术公司Alterity Therapeutics宣布，其首席执行官David Stamler医学博士将在MST Access“生命科学中的隐藏宝石”网络研讨会上发表演讲。该演讲定于2024年6月13日在澳洲和2024年6月12日在美国举行。该公司正在临床阶段开发其主要资产ATH434，用于治疗帕金森氏综合征，将提供其运营和发展概述。投资者将有在网络研讨会期间问问题的机会，活动后Alterity的网站上还将提供录音。该公告获得首席执行官David Stamler的授权，并作为提交给美国证券交易委员会的6-K表格的一部分，该表格也被纳入公司各种登记声明之中。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息